Tanatril

Quick links to important sections

Tanatril

Method of action: Antihypertensive

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tanatril

Property Description
Active Ingredient Imidapril hydrochloride
Form Tablet (Oral administration)
Pharmacological Class Angiotensin-Converting Enzyme (ACE) inhibitor
General Purpose Reduction of high blood pressure (Hypertension)
Origin Synthetic compound (Ester Prodrug)

What Type of Medicine is Tanatril (Imidapril)?

Tanatril is a prescription-only medication primarily used to manage high blood pressure and is fundamentally classified as an Angiotensin-Converting Enzyme (ACE) inhibitor. This classification is used for controlling cardiovascular pressure by modulating the body's vascular tone. Its active ingredient is Imidapril hydrochloride, a synthetic compound that targets the Renin-Angiotensin-Aldosterone System (RAAS). Unlike some older ACE inhibitors, Imidapril is classified as a non-sulfhydryl compound, a structural distinction that contributes to its long duration of action and favorable patient tolerability profile.


The Composition and Form: Understanding Imidapril as a Prodrug

Tanatril is available for oral administration as a single-ingredient product in a tablet form. The unique aspect of its composition is that Imidapril is an ester prodrug, a characteristic that differentiates it from immediately active ACE inhibitors. It must first be processed by the body through metabolism (hydrolysis) to yield its highly potent and active metabolite, Imidaprilat, before it can exert its therapeutic effect on the circulatory system. This mechanism ensures sustained systemic delivery, supporting a convenient once-daily dosing regimen typical for this type of long-acting agent.


What is the General Purpose of Taking Tanatril?

The general purpose of taking Tanatril is to assist the body in maintaining healthy arterial pressure by promoting vessel relaxation and improving overall fluid and salt balance. This is achieved through its mechanism of ACE inhibition, which prevents the formation of a powerful vasoconstrictor chemical in the bloodstream. By reducing the resistance to blood flow, Tanatril effectively fulfills its role as a key treatment in decreasing systemic arterial pressure. Tanatril is used for the long-term management of cardiovascular pressure in adults.

What side effects are possible with Tanatril?

Possible Side Effects and Safety Information

The safety profile for Tanatril (Imidapril hydrochloride) is officially documented by government regulatory bodies, classifying adverse reactions according to the frequency and the physiological system affected.

Frequency-Classified Adverse Reactions

The most commonly listed adverse reactions (classified as Common) in official product information include a dry, persistent cough, headache, dizziness, and fatigue (asthenia). Reactions listed as Uncommon may include hypotension (low blood pressure), palpitations, and disturbances such as a rash or vertigo. Reactions classified in the Rare to Very Rare categories include severe skin conditions like Stevens-Johnson Syndrome and potential impairment of the liver or pancreas.

System-Organ Class Involvement

Adverse effects are grouped into System-Organ Classes (SOCs). The most characteristic effects involve the Respiratory system (cough) and the Nervous system (headache, dizziness). Vascular disorders are noted for hypotension, and the Metabolism and Nutrition class includes the potential for hyperkalemia (elevated serum potassium).

Serious Adverse Reactions and Safety Constraints

The official label highlights certain rare but clinically significant risks. These include Angioedema, a serious reaction involving swelling of the face, tongue, or throat, and the potential for Acute Renal Failure. Safety constraints specify that the medication is contraindicated during the second and third trimesters of pregnancy due to documented risks of fetotoxicity. Furthermore, the official documents state that hypotension is more frequently observed following the initial dose and during dose escalation, representing a documented time-related safety pattern.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information for Tanatril (Imidapril)

Official regulatory documents define the overdose profile for Tanatril (Imidapril) based on the risk of excessively lowered blood pressure and life-threatening complications.

Documented Overdose Presentations

The most likely manifestation of an overdose is Hypotension (a severe drop in blood pressure), which may be accompanied by symptoms such as apathy (lethargy) or ataxia (loss of coordination). Overdose can lead to complications affecting physiological systems, including renal failure (anuria) and serious cardiovascular events, particularly in susceptible individuals.

Immediate Emergency Actions and When to Seek Urgent Help

Immediate medical attention is required for any suspected overdose, and specifically for signs of Angioedema (swelling of the face, tongue, or throat), as this carries a risk of fatal airway obstruction.

  • Emergency Therapy: Regulatory instructions state that patients experiencing angioedema require prompt administration of Epinephrine and measures to secure a patent airway.
  • Hypotension Management: For severe hypotension, patients should be placed in a supine position while medical staff initiate measures like volume repletion with intravenous fluids to restore blood pressure.

Management also includes close monitoring of vital signs, renal function, and serum electrolytes until the patient is stable.

Therapeutic Uses of Tanatril

Quick Facts

  • Condition Management: High blood pressure (Hypertension)
  • Therapeutic Support: Congestive heart failure
  • Risk Mitigation: Post-myocardial infarction care (following a heart attack)
  • Specific Renal Support: Diabetic kidney disease (Diabetic nephropathy)

Tanatril is a prescribed medication utilized in the comprehensive management of high blood pressure, medically termed hypertension. Maintaining blood pressure within an acceptable range is a key component of cardiovascular health and may support the mitigation of associated risks, such as stroke or heart attack.

The medication is also indicated for providing therapeutic support in individuals with congestive heart failure. By working on the blood vessels, it assists the heart in managing its workload, which may contribute to enhanced heart function and quality of life.

Additionally, Tanatril may be used in managing complications related to diabetes, specifically to address diabetic kidney disease. Its approved uses also include post-myocardial infarction care, where it forms part of the established treatment regimen to support patient outcomes.

Eligibility and Restrictions for Use

Who can and cannot use Tanatril? — Official Regulatory Information

The eligibility profile for Tanatril (Imidapril hydrochloride) is strictly defined by regulatory authorities, outlining populations permitted to use the medicine and those for whom use is contraindicated or restricted.

Populations for whom use is Contraindicated

Category Contraindication Rule
Hypersensitivity History of allergy to Imidapril or any other ACE inhibitor (Angiotensin-Converting Enzyme inhibitor).
Angioedema History of Angioneurotic Edema (angioedema), whether related to previous ACE inhibitor use or hereditary/idiopathic.
Pregnancy/Lactation Contraindicated in pregnancy (all trimesters) and not recommended during breastfeeding.
Renal Function Severe Renal Impairment, specifically when creatinine clearance is leq 30 mL/min or 10 mL/min, or patients undergoing hemodialysis.
Vascular Condition Patients with Renovascular Hypertension.

Age-Group and Restricted Use

The medicine is approved for the adult population. Its use is not recommended for children until efficacy and safety have been formally established. Restricted use, requiring close medical supervision, applies to patients with moderate renal impairment (creatinine clearance between 30 mL/min and 80 mL/min), severe heart failure, or volume-depletion states. These official restrictions ensure use is limited to those patient profiles where regulatory bodies have confirmed acceptable conditions for administration.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents detail specific constraints regarding the use of imidapril (Tanatril) with certain medicinal and non-medicinal products.

Documented Interaction Categories

Category of Interacting Agent Potential Clinical Outcome (Regulatory Statement)
Potassium-sparing Diuretics / Potassium Supplements Risk of hyperkalaemia (increased blood potassium levels).
Lithium Salts Risk of toxic serum lithium levels due to reduced renal excretion.
Other Antihypertensive Agents Risk of additive blood pressure lowering effects (hypotension).
Antidiabetic Drugs Risk of increased blood glucose lowering effects leading to hypoglycaemia.
Non-steroidal Anti-inflammatory Drugs (NSAIDs) Potential interference with the treatment's effect.
Rifampicin Reduces the conversion of imidapril to its active metabolite, imidaprilat.

Interaction-Related Constraints

The interaction profile includes procedural requirements and constraints on concomitant use. Patients must avoid the use of salt substitutes due to their high potassium content, which contributes to hyperkalaemia risk. Furthermore, due to the potential for excessive blood pressure reduction, the prescribing information requires that patients taking this medicine inform their surgeon or dentist prior to any procedures requiring anesthetics.

Specific monitoring is required for patients with diabetes to manage the increased risk of low blood sugar when the medicine is combined with antidiabetic treatments.

Mechanism of Action

Tanatril acts as an inhibitor of the Angiotensin-Converting Enzyme (ACE). This enzymatic inhibition interrupts the Renin-Angiotensin-Aldosterone System (RAAS) cascade by decreasing the catalytic conversion of Angiotensin I into the potent vasoconstrictor, Angiotensin II.

The resulting reduction in circulating Angiotensin II levels diminishes its binding to the AT1 receptors on vascular smooth muscle. This AT1 receptor blockade leads to a decrease in both peripheral and systemic vascular resistance. Furthermore, the inhibition of ACE concurrently reduces the enzymatic degradation of bradykinin, a vasodilator peptide. The accumulation of bradykinin further contributes to vascular smooth muscle relaxation and sustained vasodilation. This dual action modulates systemic hemodynamics, primarily through reduced vascular tone.

Dosage and Administration Information

The administration of Tanatril follows an oral, once-daily schedule. The tablets are available in strengths that include 2.5 mg, 5 mg, 10 mg, and 20 mg of Imidapril hydrochloride. Use involves swallowing the tablet whole with water, and the procedural instruction indicates that it is taken approximately 15 minutes before a meal, ideally at the same time each day to maintain consistency.

Dosing regimens vary depending on the condition being managed. For managing high blood pressure, the typical adult initial dose is 5 mg once daily, with the usual maintenance dose being 10 mg once daily, up to a maximum dose of 20 mg daily. For conditions such as heart failure or diabetic nephropathy, the initial dose begins at 2.5 mg once daily. Titration, or increasing the dose, follows a pattern where the dose may be escalated if blood pressure is inadequately controlled after a defined period of therapy, such as three weeks.

Population-specific instructions include modifications to the initial regimen. For older adults (aged 65 years or older), a reduced starting dose of 2.5 mg once daily is used, with the maximum dose typically limited to 10 mg daily. A similar initial dose reduction to 2.5 mg once daily applies to patients with specific levels of kidney impairment (creatinine clearance between 30 mL/ min and 80 mL/ min). If a dose is missed, it is taken as soon as remembered, but if it is near the time of the next scheduled dose, the missed dose is skipped; two doses are not taken at once.

Recent Clinical Evidence

Tanatril: Recent Clinical Evidence

This section provides a descriptive overview of the research studies and clinical trials that form the evidence base for the approved uses of Tanatril (Imidapril). It focuses only on the types of research available and the outcomes studied, without offering any clinical advice. Research findings reflect group patterns and may not predict individual responses.

Evidence for Use in Managing High Blood Pressure (Hypertension)

Research exploring Tanatril in conditions characterized by high blood pressure includes Randomized Controlled Trials (RCTs) where Imidapril was evaluated against placebo and active comparators. These studies focused on measuring changes in both resting and 24-hour ambulatory Blood Pressure (BP). Furthermore, research examined structural outcomes, such as patterns in the regression of Left Ventricular Hypertrophy (LVH). The longest-running studies that explore ultimate long-term outcomes generally stem from the comprehensive body of evidence covering the ACE inhibitor drug class as a whole.

Evidence for Use in Chronic Heart Failure and Post-MI Care

Research explored Imidapril in conditions such as Chronic Heart Failure (CHF) and in settings following a Myocardial Infarction (MI). Trials primarily monitored tangible physical endpoints. Studies evaluated functional measures such as exercise time and structural measures like Left Ventricular Ejection Fraction (LVEF). While the overall evidence for using this class of medication in heart failure is well-established, Imidapril-specific trials designed to track definitive long-term outcomes are generally smaller than the pivotal trials for the most recognized ACE inhibitors in this setting.

Evidence for Use in Diabetic and Non-Diabetic Kidney Disease

Tanatril was evaluated for its use in managing conditions associated with the kidneys, specifically in patients with Type 1 and Type 2 Diabetes Mellitus who show signs of early kidney involvement (nephropathy). Clinical trials monitored the Urinary Protein/Albumin Excretion Rate and biomarkers of kidney function, such as estimated Glomerular Filtration Rate (eGFR). Certain studies focusing on specific populations, such as those with non-diabetic kidney conditions, utilized comparatively small sample sizes.

What Remains Uncertain in the Research Landscape

All research has specific limitations. A key limitation for Tanatril is the reliance on ACE inhibitor class effect evidence for definitive long-term hard outcomes (like major morbidity and mortality). Furthermore, certain studies utilized modest sample sizes. The results apply only to the populations studied, and research provides context but not individual predictions.

Key Studies & References

  1. ACE Inhibitors (StatPearls - NCBI Bookshelf): Clinical Use in Heart Failure and Hypertension

Frequently Asked Questions (FAQ)

Common questions about Tanatril (FAQ)


Q: How quickly does Tanatril start lowering blood pressure?

A: Tanatril is an inactive drug (a prodrug) that the body must first convert into its active form, Imidaprilat. According to official pharmacological data, this active substance reaches its highest concentration in the bloodstream approximately 7 hours after the tablet is taken. This time frame indicates when the active substance is most concentrated in the body.


Q: Is it normal to feel dizzy when first starting Tanatril?

A: Yes, dizziness is listed in official product information as a common side effect of this medicine. Due to the possibility of feeling dizzy when starting treatment, official instructions sometimes advise taking the very first dose at bedtime. If this occurs, it is important that a healthcare provider is informed.


Q: Are there any common digestive side effects with Tanatril?

A: Official product information on gastrointestinal effects lists nausea, vomiting, and diarrhea as commonly or occasionally reported side effects. If severe digestive issues are experienced, speaking with a healthcare provider is recommended.


Q: Does Tanatril affect my sleep?

A: Studies indicate that sleep disturbances and insomnia (difficulty sleeping) have been reported as uncommon or rare side effects. These effects are classified under nervous system disorders in the official safety profile.


Q: Can I take cold and flu medicines with Tanatril?

A: Some over-the-counter cold and flu remedies contain non-steroidal anti-inflammatory drugs (NSAIDs). Regulatory documents warn about the potential for two kinds of effects: NSAIDs may interfere with the effectiveness of Tanatril, and some cold/flu components may lead to an additive blood pressure lowering effect.


Q: What are the long-term effects of taking Tanatril?

A: Tanatril is part of the ACE inhibitor drug class. For information on certain major long-term health outcomes, such as effects on major morbidity and mortality, official evidence often relies on the established research for the entire ACE inhibitor class, rather than research specific only to Tanatril.


Q: Are there generic versions of Tanatril available?

A: Yes. While Tanatril is a brand name, its active ingredient, Imidapril hydrochloride, is available in various markets from multiple manufacturers as a generic medicine.


Q: How long do most people stay on Tanatril treatment?

A: As the medicine is officially indicated for chronic, long-term conditions like high blood pressure and chronic heart failure, it is typically intended for sustained, long-term use to maintain control of these health issues.


Q: Is Tanatril used to treat conditions other than high blood pressure?

A: Yes. In addition to high blood pressure, the medicine is officially approved for the treatment of chronic heart failure and diabetic kidney disease (nephropathy) in certain patient groups.


Q: Can I crush or chew Tanatril tablets?

A: No. The official method of administration states that the tablet must be swallowed whole with water. Crushing or chewing the tablet is not authorized in the regulatory labeling.


Q: Will I need to change my salt intake while on Tanatril?

A: Official warnings strongly advise patients to avoid the use of salt substitutes. This is because salt substitutes often contain high amounts of potassium, which can increase the risk of hyperkalemia (high blood potassium levels) when taken with this medicine.


Q: Can Tanatril cause changes in my sense of taste?

A: Yes, official safety information lists taste alteration, medically known as dysgeusia, as an uncommon side effect of this medication.


Q: What happens if I stop taking Tanatril suddenly?

A: ACE inhibitors are prescribed for the chronic management of serious conditions. It is important that any decision to stop or change the medicine be discussed with a qualified healthcare professional.


Q: Is it possible for Tanatril to affect mood or cause depression?

A: Depression is listed as a rare side effect under nervous system disorders. Significant changes in mood are noted as symptoms to be aware of and discussed with a healthcare provider.


Q: What is the typical window of time for taking Tanatril each day?

A: The official instructions require that the dose be taken once daily and at approximately the same time each day to maintain consistent blood levels. However, a specific acceptable time window (e.g., within one hour) is not defined in the product information.


Q: Are there specific symptoms that require immediate medical attention while on Tanatril?

A: Angioedema, which is severe swelling of the face, tongue, or throat, is specifically noted as a serious adverse reaction. This reaction requires the immediate cessation of the medication and urgent medical attention, as noted in the regulatory warnings.


Q: Is Tanatril safe for children or adolescents?

A: The drug is generally not recommended for use in children and adolescents. This is due to the fact that official data on its safety and effectiveness in these specific age groups have not yet been formally established.


Q: What makes Tanatril different from a Beta-blocker?

A: Tanatril is classified as an ACE inhibitor, meaning it works by blocking an enzyme that narrows blood vessels. This is a distinct pharmacological mechanism from Beta-blockers, which work by blocking the effects of stress hormones like adrenaline on the heart.

How should Tanatril be stored and disposed of?

How to Store and Dispose of Tanatril

Tanatril (imidapril) tablets must be stored and disposed of according to the specific instructions provided in the official regulatory labeling to ensure product stability and safety.

Official Storage Requirements

Requirement Description
Temperature Store below 25 C; do not store above this limit.
Protection Keep the medicine in its original container to protect it from moisture.
Safety The product must be kept out of the sight and reach of children.

Official Disposal Instructions

Unused or expired Tanatril should be discarded following established governmental protocols for non-controlled substances. The preferred method is to use a community drug take-back program. If a take-back option is unavailable, the tablets should be mixed with an undesirable substance, sealed in a bag or container, and disposed of in the household trash. The medicine must not be flushed down the toilet or poured into the sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tanatril found in:

A-Z Index: